SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Zeronda Tyler

(Last) (First) (Middle)
C/O VYNE THERAPEUTICS, INC.
520 U.S. HIGHWAY 22, SUITE 204

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/18/2021
3. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Interim CFO
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 23,395(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (2) 05/16/2029 Common Stock 13,504 5.92 D
Stock Option (3) 03/19/2030 Common Stock 4,375 10.68 D
Stock Option (4) 05/06/2030 Common Stock 9,375 7.8 D
Stock Option (5) 03/04/2031 Common Stock 18,834 6.68 D
Explanation of Responses:
1. This amount includes 18,853 shares underlying unvested restricted stock units that will vest over four years following the date of grant.
2. The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on June 30, 2020 and 6.25% of the shares vest on the last day of each quarter thereafter.
3. The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on March 31, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.
4. The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on June 30, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.
5. The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2022 and 6.25% of the shares will vest on the last day of each quarter thereafter.
Remarks:
The reporting person was not granted any additional awards in connection with his appointment as interim CFO of the Issuer.
/s/ Mutya Harsch, attorney-in-fact for Tyler Zeronda 06/21/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.